Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Alberico L. Catapano, Meral Kayıkçıoğlu et al.|European Heart Journal Supplements|2016Cited by 101
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapyCarlos Aguíar, Roberto Ferrari, Lâle Tokgözoğlu et al.|Atherosclerosis Supplements|2015Cited by 84